Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Oxygen of the saccharide radical bonded directly to a nonsaccharide hetero ring or a polycyclo ring system which contains a nonsaccharide hetero ring

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514023000 - Carbohydrate (i.e., saccharide radical containing) DOAI

514025000 - O-glycoside

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514028000 The hetero ring has 8 or more ring carbons 277
Entries
DocumentTitleDate
20130045935FLAVONOID DIMERS AND THEIR USE - This invention relates to bis-flavonoid compounds of formula02-21-2013
20100041617Modulating mxa expression - The invention provides compositions and methods for inhibiting cell motility, metastatic cancer and viral infections in a mammal that involve increasing the activity or expression of MxA.02-18-2010
20120184499PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF PSEUDOLYSIMACHION LONGIFOLIUM AND THE CATALPOL DERIVATIVES ISOLATED THEREFROM HAVING ANTIINFLAMMATORY, ANTIALLERGIC AND ANTIASTHMATIC ACTIVITY - The present invention relates to a composition comprising an extract of 07-19-2012
20090170788NOVEL USE OF 1, 2, 3, 4, 6-PENTA-O-GALLOYL-BETA-D-GLUCOSE - The present invention relates to novel use of 1,2,3,4,6-penta-O-galloyl-beta-D-glucose. More particularly, the present invention relates to a pharmaceutical composition and cosmetic composition for preventing and treating skin disease, comprising 1,2,3,4,6-penta-O-galloyl-beta-D-glucose represented by formula 1 as an active ingredient. Also, the invention relates to a method for preventing and treating skin disease using 1,2,3,4,6-penta-O-galloyl-beta-D-glucose, and to the use of 1,2,3,4,6-penta-O-galloyl-beta-D-glucose.07-02-2009
20090099104SUBSTITUTED INDAZOLES-O- GLUCOSIDES - Substituted indazole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.04-16-2009
20080234209DERIVATIVES OF ASIMADOLINE WITH COVALENTLY BONDED ACIDS - The present invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with covalently bonded acids, and to the salts, solvates and prodrugs thereof, to the derivatives as medicaments, to the use of these derivatives for the preparation of a medicament, to the use of these derivatives for the preparation of a pharmaceutical composition, to a process for the preparation of the pharmaceutical compositions, to pharmaceutical compositions obtainable by this process, and to a process for the treatment of diseases which comprises the administration of the pharmaceutical composition.09-25-2008
20130085114METHOD FOR TREATING VARICOCELE OR MALE INFERTILITY USING ANTHOCYANIN EXTRACTED FROM BLACK SOYBEAN - The present invention relates to the therapeutic or ameliorating effects of anthocyanin extracted from black soybean on varicocele or male infertility. In particular, the present invention relates to a method for treating or ameliorating varicocele or male infertility using anthocyanin extracted from black soybean.04-04-2013
20100113375METHODS AND RELATED COMPOSITIONS USING SPECIFIC FLAVONOIDS AND INDANES TO REDUCE WEIGHT AND INHIBIT LIPASE, ALPHA-AMYLASE AND ALPHA-GLUCOSIDASE ACTIVITY IN MAMMALS - The present invention relates generally to methods and related compositions using flavonoids and/or indanes extracted from the stems and leaves of 05-06-2010
20100113373ANTIVIRAL SUPPLEMENT FORMULATIONS - The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure.05-06-2010
20100113372Method For Preparing Kaempferol-3-0-Rutinoside and Composition of Skin External Application Comprising Thereof - Disclosed is a method for the preparation of kaempferol-3-O-rutinoside and a composition of a skin external application comprising kaempferol-3-O-rutinoside as an active ingredient. The method for isolating kaempferol-3-O-rutinoside through hydrolysis uses an enzyme or microbe that removes the sugar selectively from kaempferol-3-O-rutinoside glycosides in a plant extract. Disclosed also is a composition of a skin external application comprising kaempferol-3-O-rutinoside that prevents skin wrinkle.05-06-2010
20100075912NOVEL MORPHINE DERIVATIVES - The present invention relates to new morphine-6-glucuronide derivatives, to pharmaceutical compositions thereof and uses thereof.03-25-2010
20120245113CLERODANE DERIVATIVES FOR MODULATION OF LEUKOTRIENE RECEPTOR ACTIVITY AND RELATED DISEASES - The use or methods of use of extracts comprising one or more special clerodane compounds against inflammatory (including allergic) diseases or conditions, as well as novel compounds of this type, said clerodane derivatives for use against inflammatory (including allergic) diseases or conditions, pharmaceutical formulations comprising them especially for use against inflammatory disease or conditions, and related embodiments; said extract and/or compound(s) for use in the treatment or in the preparation of a medicament (including a nutraceutical) for the prophylactic and/or therapeutic treatment of said disease or condition, as well as their preparation; pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s) which are useful in said prophylactic and/or therapeutic treatment, and related embodiments.09-27-2012
20120245112SYNTHESIS AND IDENTIFICATION OF NOVEL RSK-SPECIFIC INHIBITORS - A composition comprising an SL0101 [kaempferol 3-O-(3″,4″-di-O-acetyl-α-L-rhamnopyranoside)] derivative compound that has enhanced ability to inhibit RSK activity, relative to the parent compound is provided. The compounds have utility for treating any disease or conditions characterized or associated with excess or undesirable RSK activity. For example the RSK inhibitors of the present invention can be used to reduce the proliferation of neoplastic cells or for inhibiting the establishment or maintenance of an intracellular pathogenic infection by pathogens whose pathogenicity derives in part from the pathogen's ability to impede endosomal/phagosomal maturation in the host cell.09-27-2012
20090143317Quercetin Glycoside Composition and Method of Preparing the Same - The present invention provides an α-glycosyl isoquercitrin-containing novel composition which has a high in vivo absorbability, and hence exhibits a significant in vivo antioxidative activity. The present invention further provides preparation methods for such a composition. The composition contains a mixture of quercetin glycosides represented by the following formula:06-04-2009
20130079295TREATMENT OF CARTILAGE RESORPTION - Excessive articular cartilage degradation is treated or prevented by administration to a mammal such as a human 03-28-2013
20130079294EXTRACTS AND ISOLATED FLAVONOIDS FROM EUPHORBIA CUNEATA USEFUL AS ANTI-ULCER AGENTS - The present invention relates to flavonoids isolated from 03-28-2013
20130035300METHOD OF USING POMEGRANATE EXTRACTS FOR INCREASING PROSTATE SPECIFIC ANTIGEN DOUBLING TIME - A method of increasing a prostate specific antigen (PSA) doubling time in treating a patient. A subject with rising serum PSA is selected. A composition is administered to the subject comprising a therapeutically effective amount of a pomegranate extract comprising a higher content of high molecular weight polyphenol compared to pomegranate juice from arils. The therapeutically effective amount increases a prostate specific antigen doubting time. The pomegranate extract is formed from an insoluble byproduct component obtained by placing pomegranate solids in an aqueous solution, heating the aqueous solution to between about 60° F. to about 210° F., adding at least one enzyme to the aqueous solution, and removing residual insoluble solid materials from the aqueous solution.02-07-2013
20130035301CDC7 KINASE INHIBITORS AND USES THEREOF - The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B) or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.02-07-2013
20090181905CRYSTALLINE FORM OF 1' -(1-METHYLETHYL)-4' -[(2-FLUORO-4-METHOXYPHENYL)METHYL]-5' -METHYL-1H-PYRAZOL-3' -O-BETA-D-GLUCOPYRANOSIDE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS - The invention relates to a crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.07-16-2009
20090156513JUCARA AND ACAI FRUIT-BASED DIETARY SUPPLEMENTS - The present disclosure relates to stable, palatable, freeze-dried, fruit-based dietary supplements. In one embodiment, the disclosures relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The disclosure further provides for methods of making stable, palatable, freeze-dried, fruit-based dietary supplements from Açai fruit and Jucara fruit.06-18-2009
20100105630NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS - Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders.04-29-2010
20090143318DEGRANULATION INHIBITOR - An object of the invention is to find in nature a compound having a degranulation inhibitory action comparable to that of steroidal or non-steroidal degranulation inhibitors, but without any side effect such as hormone action or gastrointestinal disturbances which are observed in these inhibitors, and there is provided a degranulation inhibitor comprising as an active ingredient an ellagic acid derivative of the formula (I):06-04-2009
20090124562Versipelostatin derivative, anti-cancer agent and processes for production of the derivative and agent - Provided is a new anti-cancer agent lower in cell toxicity.05-14-2009
20110003761BIOLOGICALLY ACTIVE EXTRACT FROM DENDROBIUM PLANT, USE THEREOF AND PROCESS FOR PREPARING THE SAME - A substance having the following formula is provided.01-06-2011
20120190636COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF URINARY SYSTEM INFECTION AND METHOD THEREOF - The present invention relates to a method of reducing risk of recurrent urethritis or recurrent cystitis comprises administering to a patient with risk of recurrent urethritis or recurrent cystitis an effective amount of a composition consisting essentially of astilbin and chlorogenic acid.07-26-2012
20120225833COMPOSITION FOR TREATING MENTAL HEALTH DISORDERS - A composition of three compounds each selected from a selective re-uptake inhibitor of serotonin, a monoamine oxidase inhibitor, and a phosphodiesterase inhibitor, such that all three compounds are different and are naturally occurring.09-06-2012
20130065843Phenolic Compositions Derived From Apple Skin And Uses Thereof - Described herein are phenolic compositions derived from apple skins. In particular, described herein are flavonoid-rich fractions derived from apple skin extract. The compositions are useful in the prevention and treatment of conditions associated with oxidative stress and/or inflammation, including certain neurodegenerative diseases. Methods of producing the compositions are also described.03-14-2013
20120115800Pigment Aggregates - The invention provides a method for in vitro formation of anthocyanic vacuolar inclusion (AVD-like structures, the method comprising the step of combining at least one anthocyanin, and b) at least one lipid. The invention also provides AVI-like structures produced by the method of the invention, compositions comprising such AVI-like structures, and uses of such AVI-like structures.05-10-2012
20120238515METHODS FOR PREVENTING OR TREATING SARCOPENIA AND MUSCLE ATROPHY IN ANIMALS - The invention provides methods for one or more of preventing or treating sarcopenia and muscle atrophy in animals. The methods comprise administering isoflavones to the animals, preferably in amounts of from about 0.001 to about 10 g/kg/day.09-20-2012
20120238514NOVEL CRYSTALLINE HETEROAROMATIC FLUOROGLYCOSIDE HYDRATES, PHARMACEUTICALS COMPRISING THESE COMPOUNDS AND THEIR USE - The invention relates to crystalline hydrates of the formula I09-20-2012
20120238513METHOD FOR INHIBITING ACTIVATION OF MACROPHAGES - Provided is a method for inhibiting the activation of macrophages in a subject, comprising administrating to the subject an effective amount of an active component selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, and a pharmaceutically acceptable ester of the compound, and combinations thereof:09-20-2012
20120270819USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE - Use of compounds with SGLT-1/SGLT-2 inhibitor activity for producing medicaments for treatment of bone diseases The invention relates to the use of compounds with SGLT-1/SGLT-2 inhibitor activity for producing medicaments for treatment of bone diseases like osteoporosis. Preferred is the use of compounds of the formula I in which the radicals have the stated meanings.10-25-2012
20130165396Apple Skin Extracts for Treating Cardiovascular Disease - Pharmaceutical and nutraceutical compositions and methods for treating cardiovascular disease, comprising apple skin extracts which can reduce cholesterol levels and inhibit low density lipoprotein (LDL) oxidation in a subject, are provided.06-27-2013
20100261663Compositions Containing Harpagoside and Paeoniflorin and Methods for Treatment of Conditions Associated with Pain, Inflammation, Arthritis and Symptoms Thereof - The present invention is directed to compositions incorporating purified herbal ingredients for the treatment of conditions such as pain, inflammation, arthritic conditions and other chronic rheumatic diseases, muscle spasms, and headache, as well as methods for their use. The compositions incorporating purified herbal ingredients can incorporate the following combinations of ingredients: (1) harpagoside and paeoniflorin; (2) harpagoside, paeoniflorin, and bioperin; (3) harpagoside and bioperin; and (4) paeoniflorin and bioperin.10-14-2010
20110281808Composition and Method for Increasing Pre Workout Thermogenics - The present invention provides a composition for causing a simultaneous and synergistic increase in central nervous system activity and thermogenesis in a mammal, comprising Yerba Mate as a source of caffeine, hordenine and naringin. The present invention further provides a composition for causing a simultaneous and synergistic increase in central nervous system activity and thermogenesis in a mammal, comprising from 0.0001 g to 0.25 g of caffeine from Yerba Mate leaves, from 0.00001 g to 0.75 g of hordenine from barley and from 0.00001 g to 0.75 g of naringin sourced from grapefruit. The present invention finally provides a method for causing a simultaneous and synergistic increase in central nervous system activity and thermogenesis in an mammal prior to physical exercise, said method comprising providing a composition comprising a source of caffeine, hordenine and naringin and administering the composition to an mammal prior to physical exercise.11-17-2011
20100197619CYCLIN-DEPENDENT PROTEIN KINASES INHIBITORS OF SCUTELLARIA FLAVONOID ORGANIC AMINE DERIVATIVES, SYNTHESIS AND USE THEREOF - The present invention provides a series of cyclin-dependent protein kinases (Cdks) inhibitors, 08-05-2010
20130023489COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING DISEASES AND ENVIRONMENTALLY INDUCED HEALTH DISORDERS - Nutraceutical or pharmaceutical compositions, functional foods, extracts, dietary supplements and food/feed additives enriched in phytochemicals having antioxidant and/or anti-inflammatory activity may be derived from the skin, pith, or cortex from stem tubers of select potato cultivars, including an Onaway potato cultivar optionally complemented by a Russet Burbank, Purple Valley or Bora Valley cultivar. These cultivars and combinations thereof provide a useful antioxidant source enriched in ferulic acid, caffeic acid, chlorogenic acids, ascorbic acid, anthocyanins, and rutin, isomers or derivatives thereof having antioxidant and/or anti-inflammatory activity.01-24-2013
20100216729Cancer cell growth inhibition by black bean (Phaseolus vulgaris L) extracts - A group of phytochemical compounds extracted from whole germinated or not germinated black beans (08-26-2010
20090029928PEELING PROCESS AND COMPOSITION - Process for the treatment of visible and/or tactile irregularities of human skin, by applying topically, to the skin, a composition containing at least one hydroxy acid chosen from α-hydroxy acids, β-hydroxy acids, α-keto acids, β-keto acids, and mixtures thereof, and at least one cationic polymer, leaving the composition in contact with the skin for a period of time sufficient for the composition to act, and optionally, removing the composition by rinsing. Associated compositions.01-29-2009
20110288038HESPERIDIN-CONTAINING COMPOSITION - This invention relates to a composition that stably contains hesperidin. The present invention provides a composition containing (A) hesperidin, (B) at least one dihydric alcohol selected from the group consisting of ethylene glycol, diethylene glycol, triethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, and 3-methyl-1,3-butanediol, and (C) a sugar alcohol. In the composition, the decomposition of hesperidin is suppressed and hesperidin is stably contained.11-24-2011
20110301107DERIVATIVES OF MORPHINE-6-GLUCURONIDE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS - The disclosure relates to derivatives of morphine-6-glucuronide of formula (I)12-08-2011
20110301106Use of Icariside II in Manufacture of Products for Preventing or Treating Male or Female Sexual Dysfunction - The present invention provides the use of icariside II or extract comprising thereof in manufacture of products for preventing or treating male or female sexual dysfunction, in particular, the use for improving pathological or organical changes in erectile tissues of patients with erectile dysfunction.12-08-2011
20110294750SURFACE STERILISATION BY MISTING WITH A BIOFLAVANOID SOLUTION - There is described a method of sterilizing surfaces using flavonoids, for example mixtures containing inter alia naringin and neohesperidin, by misting.12-01-2011
20100305053USE OF HESPERIDIN OR OF A DERIVATIVE THEREOF FOR THE PREVENTION AND/OR TREATMENT OF SLACKENED SKIN - The present invention relates to the oral use of an effective amount of hesperidin or of a derivative thereof as a skin finning agent.12-02-2010
20090312276Compositions and Methods for Treating Cancer - Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.12-17-2009
20090099103COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER - The invention relates to a combination comprising an Erb-B and VEGF receptor inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.04-16-2009
20100113374METHODS AND RELATED COMPOSITIONS USING SPECIFIC FLAVONOIDS AND INDANES TO REDUCE WEIGHT AND INHIBIT LIPASE, ALPHA-AMYLASE AND ALPHA-GLUCOSIDASE ACTIVITY IN MAMMALS - The present invention relates generally to methods and related compositions using flavonoids and/or indanes extracted from the stems and leaves of 05-06-2010
20110263519REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO - The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations.10-27-2011
20090088393METHODS AND FORMULATIONS FOR CONVERTING INTRAVENOUS AND INJECTABLE DRUGS INTO ORAL DOSAGE FORMS - Oral dosage compositions for drugs normally given intravenously such as Paclitaxel, containing a plant sterol to enhance solubility and a small intestine efflux inhibitor to prevent P-glycoprotein from being a barrier to absorption.04-02-2009
20100267653USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY - The invention provides coumarin compounds, in particular glycosidic coumarin compounds, useful in the treatment of dermatophyte fungal infections.10-21-2010
20100120705COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.05-13-2010
20110136751Use of Polyphenols in the Treatment of Cancer - The present invention relates to polyphenol compounds, compositions thereof, and methods for treating or preventing cancer in a subject, the methods comprising co-administering to a subject an effective amount of two or more polyphenol compounds or a polyphenol composition thereof.06-09-2011
20100099633METHOD FOR ENHANCING NUTRIENT ABSORPTION WITH ASTRAGALOSIDES - The present application relates to a method for enhancing absorption of a nutrient in a subject in need thereof with an effective amount of an isolated astragaloside compound.04-22-2010
20110201565LUTEOLIN AND DIOSMIN/DIOSMETIN AS NOVEL STAT3 INHIBITORS FOR TREATING AUTISM - The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation/phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction of autistic phenotype induced by IL-6 through inhibition of STAT3 activation.08-18-2011
20090088394METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT - Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide for the increase of efflux transporter activity at blood-brain, blood-CSF and placental-maternal barriers to increase the efflux of drugs and other compounds from physiological compartments, including central nervous system and fetal compartments.04-02-2009
20090275527SKIN AGING TREATMENT COMPRISING PAEONIFLORIN - The present invention relates to a skin aging treatment comprising paeoniflorin as an active ingredient. Since paeoniflorin is effective in significantly inhibiting and improving intrinsic skin aging, significantly inhibiting and improving DNA impairment and skin wrinkling caused by UV and improving existing wrinkles, a cosmetic composition and a pharmaceutical composition comprising paeoniflorin may become a very useful skin aging treatments.11-05-2009
20090170789Antioxidants for preventing and treating diseases caused by oxidative stress - Antioxidant compositions for the treatment and prophylaxis of illnesses associated with oxidative stress and lack of oxygen in the human body, comprising a complex of a metal selected from the group consisting of iron, copper, zinc and manganese with rutin and ascorbic acid and/or dihydroascorbic acid. Methods for synthesizing the antioxidant compositions and granulates, tablets and capsules containing antioxidant compositions are also provided.07-02-2009
20090036387NOVEL CHEMICAL ENTITIES AFFECTING NEUROBLASTOMA TUMOR-INITIATING CELLS - Disclosed are neuroblastoma tumor-initiating cell inhibiting compositions comprising chemical entities capable of affecting neuroblastoma tumor-initiating cells. Pharmaceutical preparations that include these chemical entities are also provided for the treatment of neuroblastoma. These pharmaceutical preparations are suitable for the treatment of humans, and are particularly suited for the treatment of children of 12 years of age or younger having neuroblastoma. The compositions and pharmaceutical preparations posses reduced normal cell cytotoxicity. The compositions and pharmaceutical preparations may be used alone or together with other conventional neuroblastoma preparations as part of a clinical regimen in the treatment and management of neuroblastoma.02-05-2009
20120295859METHOD FOR TREATMENT OF MALARIA - A method for treatment of malaria including administering to a patient in need thereof a flavonoid glycoside compound.11-22-2012
20080280839Anti-Cancer Activity of Androsace Umbellata Merr. Extract and Contained Triterpene Saponin - The present invention relates to an 11-13-2008
20080287375Selective Glycosidase Inhibitors, Methods of Making Inhibitors, and Uses Thereof - The invention comprises compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions containing the compounds or prodrugs of the compounds. The invention also comprises animal models and methods of making the animal models for studying diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc, and treatment of such diseases and disorders. The invention also comprises methods of treating such diseases and disorders. The invention also comprises methods of making the compounds, and methods of making selective glycosidase inhibitors.11-20-2008
20080312166Reversal core pharmaceutical system and method - A medication delivery system is disclosed to mitigate or reverse the pharmacologic effect of a medication beyond the desired therapeutic window. The system provides sequential delivery of medications including a first agent which induces a physiologic change, a second agent for reversing the physiologic change, and a medication release delaying agent for delaying the release of the second agent so that, upon receipt of the medication delivery system into the body the first agent is released before the second agent so that the physiologic effect of the first agent is mitigated by the second agent. The system can be a pill with the first agent comprising an outer medication and the second agent an inner medication with the medication release delaying agent intermediate the outer medication and the inner medication. In an example, the first agent can comprise a sleep aid and the second agent an arousal agent.12-18-2008
20100279961PHARMACEUTICAL COMPOSITION HAVING A TRIHYDROXY-CHROMENONE DERIVATIVE - The invention relates to a pharmaceutical composition comprising a glucuronate, glucoside, and/or sulfo conjugate of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, or such a conjugate of a derivative of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, or a physiologically well tolerated salt of such a conjugate.11-04-2010
20080269144Synthesis of Inhibitors of P90Rsk - The synthesis of the naturally occurring kaempferol glycoside SLO1O1-1, as well as analogs thereof, has been accomplished, as has its biochemical evaluation. SLO1O1-1 exhibits selective and potent p90 Rsk inhibitory activity at nanomolar concentrations without inhibiting the function of upstream kinases such as MEK, Raf, or PKC. The synthetic scheme of the invention verified the structural assignment of the natural SLO1O1-1 product and has provided access to material sufficient for detailed biological evaluation.10-30-2008
20110207683NATURAL COLORANT AND METHODS THEREOF - To provide a material composed mainly of a material derived from dragon fruit having to provide a supplement, a drug, a cosmetic or a food produced by using the material. The invention provides a material derived from dragon fruit, especially, a powder of dragon fruit, and a supplement, a drug, a cosmetic or a food containing the above material as a component.08-25-2011
20110207684NEW LOW SIDE EFFECT PHARMACEUTICAL COMPOSITION CONTAINING ISONIAZID - The present invention features a novel, low side-effect pharmaceutical compound complex, comprising the pharmaceutically effective dose of isoniazid (INH) and pharmaceutically effective dose of one of the following compounds. Said compound was selected from the following groups of compounds: Nordihydroguaiaretic acid, Trans-Cinnamaldehyde, Daidzein, Isovitexin, Kaempferol, disulfuram, β-Myrcene, Quercetin, (−)-Epigallocatechin-3-gallate, (+)-Limonene, Myricetin, Quercitrin, Luteolin-7-Glucoside, Morin, Neohesperidin, Hesperidin, Capillarisin, (−)-Epigallocatechin, Luteolin, Hyperoside, Ethyl Myristate, Tamarixetin, Phloretin, Baicalein, Rutin, Baicalin, Apigenin, Naringenin, Hesperetin, (+)-Epicatechin, (−)-Epicatechin-3-gallat, Isoliquritigenin, Silybin, Vitexin, Genistein, Isorhamnetin, gallic acid, Diosmin, 6-Gingerol, (+)-Taxifolin, Wongonin, Protocatechuic acid, (+)-Catechin, β-naphthoflavone, Embelin, Trans-Cinnamic acid, (−)-Epicatechin, Phloridzin, Puerarin, Umbelliferone, Brij 58, Brij 76, Brij 35, Tween 20, Tween 80, Tween 40, PEG 2000, PEG 400, Pluornic F68, and PEG 4000. The novel, low side-effect compound complex which contains pharmaceutically effective doses of isoniazid (INH), disulfuram (DSF) and/or a third compound, bis-nitrophenyl phosphate (BNPP) can reduce isoniazid (INH)-induced side effects, e.g. hepatotoxicity, etc.08-25-2011
20100004188SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES - This invention relates to to substituted benzimidazole-O-glucosides, benztriazole-O-glucosides, and benzimidazolone-O-glucosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.01-07-2010
20090137499BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE - The present invention relates to a benzylphenyl glucopyranoside derivative having an excellent inhibitory effect on human SGLT1 and/or SGLT2 activity. There is provided a compound or a pharmacologically acceptable salt thereof represented by the following general formula (I):05-28-2009
20110224157HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS - The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.09-15-2011
20090203633PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF - The present invention provides pyrazole derivatives represented by the general formula:08-13-2009
20090082285Adiponectin expression promoter - To prevent or alleviate various pathologies caused by lifestyle-related diseases, etc., the present invention provides a substance having an effect of promoting the expression and elevating the expression level of adiponectin, and applications thereof. An adiponectin expression promoting agent containing, as an active ingredient, at least one cyanidin compound selected from the group consisting of cyanidin and cyanidin glycosides can be applied to pharmaceutical or food compositions for use in applications in which the pharmacological effects of adiponectin are utilized.03-26-2009
20090203632COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE - A method for treating contracture is provided that includes administering to a patient in need thereof a composition that includes a therapeutic agent effective in treating contracture. Compositions, devices, and kits for use in treating contracture are also described.08-13-2009
20090105165SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES - This invention relates to substituted benzimidazole-O-glucosides, benztriazole-O-glucosides, and benzimidazolone-O-glucosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.04-23-2009
20090221517Biologically Active Compounds - Compounds having useful biological activity, particularly antioxidant and anti-inflammatory activity, derived from 09-03-2009
20100160244METHODS AND COMPOSITIONS FOR ENHANCING COLLAGEN, PROTEOGLYCAN, AND GLUTATHIONE SYNTHESIS IN THE SKIN - A composition for application to the skin can stimulate the in vivo synthesis of collagen and proteoglycans and improve the appearance of the skin, increasing its elasticity and fullness. In general, a composition according to the present invention comprises: (1) an antioxidant compound in a quantity sufficient to enhance collagen synthesis in the skin; (2) an organic penetrant in which the antioxidant compound is soluble in a sufficient quantity that a concentration of the antioxidant compound sufficient to enhance collagen synthesis can be applied topically and penetrate the skin; (3) a mixture of essential amino acids or hydrolyzed whey protein; (4) a supplemental source of sulfur; and (5) a topical pharmaceutically acceptable carrier. The antioxidant compound can be lipoic acid or a lipoic acid analogue or derivative. The organic penetrant is preferably benzyl alcohol. Other ingredients, such as esters of tocopherol and ascorbic acid, can be included.06-24-2010
20100016246FOOD COMPOSITION FOR FUNCTIONAL FOODS AND NUTRITIONAL SUPPLEMENTS - A food composition for functional foods and nutritional supplements is for preventing, reducing or treating cardiovascular diseases or mild manifestations thereof, obtained from the combination of extracts derived from citrus species, which contain between 25 and 80% by weight of hesperidin; between and 10% by weight of isonaringin; between 0.5 and 1% by weight of eriocitrin; and between 0.1 and 1% by weight of diosmin and the use of the composition in functional foods and nutritional supplements.01-21-2010
20090093419GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES - The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula:04-09-2009
20100160245Quercetin-Containing Compositions - This invention relates to a composition containing quercetin, vitamin B3, and vitamin C. Also disclosed is a method of using the composition for enhancing physical or mental performance or treating various diseases or disorders.06-24-2010
20100197618EXTRACT OF REHMANNIA GLUTINASA LIBOSCH FOR REDUCING BLOOD SUGAR, REDUCING BLOOD FAT, TREATING LEUKEMIA, AND PREPARATION METHOD USES THEREOF - The present invention relates to a 08-05-2010
20110059913COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL INDICATIONS - The present invention relates to identification of 03-10-2011
20130123204METHOD FOR TREATING HEPATITIS B - The disclosure provides a method for treating hepatitis B, including: administering an effective amount of proanthocyanidins wherein the formula of a monomer of the proanthocyanidins is shown as Formula (I):05-16-2013
20120196818METHOD FOR PREPARING POLYPHENOL EXTRACTS FROM SPINACH LEAVES - A method for preparing a concentrated spinach extract in a liquid or dry form and having a polyphenol titer greater than or equal to 50% is described. The method includes a step of purifying a raw spinach extract in a liquid form using a liquid-liquid extraction technique with a food oil.08-02-2012
20100234311Methicillin-Resistant Staphylococcus Aureus Active Metabolites - This present provides kaempferol-3-(2-E,3-Z-di-p-coumaroyl)-rhamnoside, kaempferol-3-(2-Z-3-E-di-p-coumaroyl)-rhamnoside, and kaempferol-3-(2,3-di-Z-p-coumaroyl)-rhamnoside compounds useful as a new class of anti-bacterial agents. These compounds are extracted from 09-16-2010
20100227827METHOD OF INCREASING TRYPTOPHAN AND NICOTINAMIDE LEVELS IN VIVO - Novel methods of increasing the biosynthesis of aromatic amino acids and compositions containing the precursors of said aromatic amino acids or nicotinamide and methods of use thereof. In addition, methods of monitoring the therapeutic effects of an anti-oxidant therapy by measuring serum protein thiols as a surrogate or predictor of such therapy are disclosed.09-09-2010
20090075914DEUTERIUM-ENRICHED ODIPARCIL - The present application describes deuterium-enriched odiparcil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20100210573COMPOUND AND COMPOSITIONS FOR TREATMENT OF DISEASE - The present invention relates to flavonoids and to flavonoid-containing compositions for use in the treatment of parasites.08-19-2010
20090197821COMPOSITIONS AND METHODS FOR THE DELIVERY OF POORLY WATER SOLUBLE DRUGS AND METHODS OF TREATMENT - The present embodiment of the invention is generally directed to compositions comprising suspensions of poorly water-soluble compounds recrystallized in nanoparticulate sizes ranging from 0.1 to 5 μm. In addition, the embodiment of the invention is directed to methods for preparation and administration of these compositions to a patient for prevention and treatment of disease states. In particular, the embodiment of the invention is directed to compositions comprising suspensions of poorly water-soluble compounds, such as antimitotics and antibiotics, in nanoparticulates and methods of prevention and treatment of chronic disease states, such as cancer, by intraperitoneal and intravenous administration of such compositions08-06-2009
20110112044NOVEL USES OF D-MANNOPYRANOSE DERIVATIVES - The invention relates to the use of mannose-6-phosphate (M6P) and of certain derivatives thereof for controlling angiogenesis and ligament regeneration and/or cartilage reconstruction. The MP6 and certain derivatives thereof can particularly be used for preparing a pharmaceutical composition used for ligament regeneration and/or cartilage reconstruction.05-12-2011
20090275525USE OF A LACTOSE-DERIVED C-GLYCOSIDE COMPOUND AS AN AGENT FOR ACTIVATING AND REGULATING CUTANEOUS IMMUNITY - The present invention relates to novel lactose-derived compounds of general formula (I) and to their use as agents for stimulating the immune system of the skin and/or as immunoregulators, and for preparing a composition containing a cosmetically or pharmaceutically acceptable medium, intended in particular to prevent and/or limit the appearance of cutaneous immune imbalances, in particular related to environmental stresses.11-05-2009
20090275526Mucoadhesive nanoparticles for cancer treatment - The present invention relates to a pharmaceutical composition which includes nanoparticles. The nanoparticles include a glyceryl monooleate or monolinoleate (or other mono fatty acid ester); a chitosan; and a cancer therapeutic agent, such as gemcitabine, taxanes, and hydrophobic cancer therapeutic agents). Also disclosed are methods for preparing such nanoparticles and pharmaceutical compositions, as well as methods for treating breast, pancreatic, colon, prostate, and other cancers by parenterally, intravenously, or otherwise administering such nanoparticles and pharmaceutical compositions.11-05-2009
20080274987Novel alpha glucosidase activator, pulicarside 1 - A new ent-kaurane type diterpene glucoside, pulicarside (1) was isolated from 11-06-2008
20130130998Analogues of Etoposide for the Treatment of Tumours - Compounds for treatment of a patient having a tumour that is metastatic and/or that reduces an organ function, wherein the compounds are of the general formula:05-23-2013
20100331271Use of Acacetin and Related Compounds as Potassium Channel Inhibitors - This invention provides a method for treating or preventing human atrial arrhythmia (fibrillation) using the leading flavone compound acacetin, and its derivatives and analogues that inhibit the ultra-rapidly-activating delayed rectifier potassium current (I12-30-2010
20110034404PEST CONTROL AGENTS - Disclosed is a composition for use as a pest control agent, comprising a compound represented by formula (I) or an agriculturally and horticulturally acceptable salt thereof as active ingredient and an agriculturally and horticulturally acceptable carrier:02-10-2011
20120270818HDAC 6 INHIBITOR-BASED METHODS FOR TREATING CANCER - This invention provides methods for treating a subject afflicted with cancer, comprising concurrently administering (i) an HDAC 6-selective inhibitor and (ii) a suitable cytotoxic agent such as SAHA, doxorubicin or etoposide. This invention also provides methods for inducing the death of a transformed cell such as a cancer cell, comprising concurrently contacting the cell with (i) an HDAC 6-selective inhibitor and (ii) a suitable cytotoxic agent such as SAHA, doxorubicin or etoposide.10-25-2012
20100286075AMPHIPHILIC BLOCK COPOLYMER MICELLE COMPOSITION CONTAINING TAXANE AND MANUFACTURING PROCESS OF THE SAME - A taxane-containing amphiphilic block copolymer micelle composition, including taxane, an amphiphilic block copolymer containing a hydrophilic block and a hydrophobic block, and an osmolality adjusting agent, is described. Also described are a method for preparing the same composition. The composition has excellent stability so that it can prevent rapid release of a drug and can improve a desired pharmacological effect. Additionally, the method enables highly efficient preparation of the composition.11-11-2010
20110086811HIGH-CONCENTRATION RUTIN-CONTAINING DRINK - It is an object of the present invention to provide a packaged high-concentration rutin-containing drink suppressed the occurrence of the precipitation though it contains rutin in a high concentration. According to the invention, a packaged high-concentration rutin-containing drink includes rutin and quercetin is provided. The concentration of rutin is in a range from 70 to 1100 ppm and the ratio [(A)/(B)] by weight of (A) rutin to (B) quercetin is 3.7 to 58.0.04-14-2011
20100016247USING BUDDING YEAST TO SCREEN FOR INHIBITORS OF AURORA KINASES - Methods of screening for novel Aurora kinase inhibitors in higher organisms are provided using hypomorphic ipl1 mutant yeast cells. Putative Aurora kinase inhibitors identified by present screening methods may be useful in treating individuals having a proliferative disease, such as cancer. Chemical compounds identified by present methods as selectively inhibiting growth of hypomorphic ipl1 mutant yeast cells may be used in compositions. Compositions or compounds identified by such screening methods may be administered to an individual in need thereof.01-21-2010
20110152210POLYPHENOL COMPOUNDS FOR INHIBITING PROTEASOME AND USES THEREOF - Synthetic polyphenolic compounds of formula (I), their modes of synthesis, and pharmaceutical compositions thereof are provided herein. Use of the compounds and compositions described herein for inhibiting proteasomal activity and for treating cancer is also provided.06-23-2011
20120245111FLAVANONES-CONTAINING FOOD COMPOSITIONS - The present invention relates to food products comprising flavanones. In particular, it relates to food products comprising hesperidin having improved stability. The present invention also concerns processes for the manufacturing of food products comprising said flavanones, especially hesperidin and to the use of the food products in the manufacture of compositions for the improvement of bone and skin health. Said flavanones are subjected to heating in water to a temperature of at least 138° C.09-27-2012
20130157966NEW USE OF ICARIIN AND EPIMEDIUM FLAVONOIDS CONTAINING ICARIIN - New use of icariin and Epimedium flavaoids containing icariin is provided by the present invention. Specifically, uses of compounds of Formula I or Epimedium containing compounds of formula I, Epimedium flavanoids, or extracts of Epimedium in manufacturing medicaments for treating, preventing, reducing and/or relieving diseases and/or conditoins related to neural myelin sheath impairments, or use of above materials in manufacturing medicaments for relieving demyelination and/or promoting repair of myelin sheath are provided by the present application, wherein, R06-20-2013
20110251144MOLECULAR MODULATORS OF THE WNT/BETA-CATENIN PATHWAY - The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.10-13-2011
20110082098NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE - Novobiocin analogues are useful in methods of treating, inhibiting, and/or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof.04-07-2011
20100311675NOVEL METHOD FOR PREPARING PURIFIED EXTRACTS OF HARPAGOPHYTUM PROCUMBENS - The present invention relates to a method for preparing a concentrated extract of 12-09-2010
20100144658NOVEL ANTIBIOTICS, BISPOLIDES A1, A2, AND A3 AS WELL AS BISPOLIDES B1, B2A, B2B AND B3 AND PROCESSES FOR PRODUCING SAID ANTIBIOTICS - Seven novel antibiotic substances could be produced by cultivation of a microbial strain which has been isolated from a soil sample and which is designated as 06-10-2010
20110251143STABLE ELSAMITRUCIN SALT FORMULATIONS - Formulations containing stable forms of elsamitrucin salts are provided. These formulations are useful for treating neoplastic diseases and conditions.10-13-2011
20100004187COBALT-AMINE BASED METAL COMPLEX AS AN ANTIBACTERIAL COMPOUND - Disclosed herein is a method of: administering to a subject suspected of being infected with a bacterium, a composition of a cobalt (III) compound having the formula CoR01-07-2010
20110257119Microcirculation improvement and/or treatment - This invention relates to compositions, and methods of use thereof, for improving microcirculation in a diabetic subject, and for dietary management of diabetes-associated condition(s) comprising administering certain polyphenols such as flavanols, procyanidins, or pharmaceutically acceptable salts or derivatives thereof to the subject in need thereof.10-20-2011
20110257118Vascular Circulation in Peripheral and/or Small Blood Vessels - The invention relates to compositions, and methods of use thereof, containing polyphenols such as flavanols, procyanidins, their derivatives and epimers thereof, for improving vascular circulation in peripheral and/or small blood vessels.10-20-2011
20120202759ISOFLAVONE COMPOSITIONS FOR REDUCING ACCUMULATION OF BODY FAT IN MALE MAMMALS, AND METHODS FOR THEIR USE - Edible compositions useful for weight management in male animals are disclosed. The compositions comprise one or more isoflavones or isoflavone metabolites and are particularly useful for reducing or preventing the accumulation of body fat. Also disclosed are methods useful for weight management in an animal utilizing compositions comprising one or more isoflavones. The compositions and methods are particularly useful for the reduction or prevention of body fat accumulation during periods of excess caloric intake, and preferably have a sparing effect on lean body mass.08-09-2012
20110053874USE OF FLAVONOIDE COMPOUNDS FOR THE PROPHYLAXIS AND THERAPY OF ISCHAEMIC OR INFLAMMATORY HEART AND CARDIOVASCULAR DISEASES - The present invention relates to the use of flavonoid compounds, particularly quercetin-3-O-β-D-glucuronide and kaempferol-3-O-β-D-glucuronide and their glucosides, for preventing diseases of the heart. Red vine leaf extract has proved a particularly advantageous source of the flavonoid compounds in question.03-03-2011
20110053873HSP90 INHIBITORS - The invention relates to HSP90 inhibiting compounds consisting of the formula: (I) wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.03-03-2011
20110053872Pharmaceutical Composition For Preventing And Treating Diabetic Nephropathy And The Preparation Method Thereof - The present invention relates to a pharmaceutical composition for preventing and treating diabetic complications, mainly referring to diabetic nephropathy, and the pharmaceutical composition comprises one or both of calycosin and calycosin-7-O-β-D-glucoside as 0.1˜99.5% by weight based on the total weight of the composition, and the conventional drug carrier. The pharmaceutical composition could significantly prevent and treat diabetic nephropathy, with the convenience of quality control and administration, which provides a new drug candidate for patients with diabetic nephropathy.03-03-2011
20110028415USE OF 3-(INDOLYL)- OR 3-(AZAINDOLYL)-4-ARYLMALEIMIDE DERIVATIVES IN LEUKENIA MANAGEMENT - The present invention relates to the use of a compound of formula (I) wherein R02-03-2011
20110086810HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE - The present invention provides hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.04-14-2011
20100323977Mucoadhesive nanoparticles for cancer treatment - The present invention relates to a pharmaceutical composition which includes nanoparticles. The nanoparticles include a glyceryl monooleate or monolinoleate (or other mono fatty acid ester); a chitosan; and a cancer therapeutic agent, such as gemcitabine, taxanes, and hydrophobic cancer therapeutic agents). Also disclosed are methods for preparing such nanoparticles and pharmaceutical compositions, as well as methods for treating breast, pancreatic, colon, prostate, and other cancers by parenterally, intravenously, or otherwise administering such nanoparticles and pharmaceutical compositions.12-23-2010
20110257117OLIVE COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS - A method of treating an inflammatory condition with a hydroxytyrosol-rich composition. Improvement is monitored as a reduction in the levels of a biochemical marker such as homocysteine or C-reactive protein. The composition may be administered in an amount and for a period sufficient to effect a drop in the level of the biochemical marker.10-20-2011
20120302515METHODS FOR PRODUCING PHYTOEXTRACTS FROM VEGETATION WATERS AND OLIVE OIL POMACES AND COMPOSITIONS OBTAINED THEREBY - Methods are provided for obtaining phytoextracts from vegetation waters and pomaces coming from olive milling. Such methods may be based on combining physical-chemical and enzymatic pre-treatment methods, membrane tangential filtration and vacuum evaporation. Such methods allow eco-sustainable and efficient extraction of the active ingredients involved. Compositions resulting from such methods are also provided.11-29-2012
20110130356MORPHINE AND MORPHINE PRECURSORS - Methods and materials related to the use of morphine, morphine precursors (e.g., reticuline), and inhibitors of morphine synthesis or activity to treat diseases, to reduce inflammation, or to restore normal function are provided.06-02-2011
20110190228SANITISING COMPOSITIONS - The present invention relates to a sanitising composition, particularly to a sanitising composition for combating undesired microorganisms, especially those present on food products such as salads, poultry, cut fruit, and in hospital environments. There is provided a sanitising composition comprising at least one flavonoid, and at least one a surfactant, wherein the composition is acidic.08-04-2011
20120309702DYNAMIC INHIBITORS OF HEAT SHOCK PROTEIN 90 - An inhibitor of heat shock protein 90 (HSP90) can include a coumermycin A1 analog having a structure that inhibits HSP90 greater than coumermycin A1. That is, the coumermycin A1 analog is not coumermycin A1. The coumermycin A1 analog can have an antiproliferative biological activity, which can be superior to coumermycin A1. The activity can include the coumermycin A1 analog inhibiting a C-terminus of HSP90.12-06-2012
20120309703AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF - The present invention relates to agonists of the human bitter-taste receptors hTAS2R14, hTAS2R10 and hTAS2R4 and their role in bitter taste transduction. The invention also relates to methods for identifying molecules that modulate, e.g. suppress, or enhance hTAS2R14, hTAS2R10 and hTAS2R4 bitter taste transduction or bitter taste response.12-06-2012
20120309701COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS - The present invention encompasses compounds and methods for treating urinary tract infections.12-06-2012
20090176718Berry Preparations For Treatment Of Diabetes And Metabolic Syndrome - The present invention provides a pharmaceutical composition for the treatment of a disordered metabolism syndrome comprising anthocyanin-rich extracts from berries. The present invention further provides a method for treating a disordered metabolism syndrome utilizing anthocyanin-rich extracts from berries.07-09-2009
20100190733Methods of Treating Muscular Dystrophies - The invention relates to methods of treating Duchenne muscular dystrophy with flavonoids. The methods may include (a) providing a pharmaceutical composition comprising a therapeutically effective amount of flavonoid, and (b) administering the composition to a human patient, wherein the flavonoid comprises an isoflav-4-one with at least one of the carbons located at positions 8, 7, 6, 5, 2, 2′, 3′, 4′, 5′, or 6′ modified by an alcohol group. Alternatively, the flavonoid may comprise (1) a flavan-3-ol with at least one of the carbons located at positions 8, 7, 6, 5, 4, 2′, 3′, 4′, 5′, or 6′ modified by an alcohol group, or (2) a Free-B-Ring flavone with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by an alcohol group and with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by a glycoside group.07-29-2010
20110190230Betalain Compositions and Uses Thereof - Contemplated compositions and methods employ betalains for treatment of various conditions, and especially osteoarthritis, sinusitis, contact dermatitis, acne, an allergic condition, reduced mental alertness, reduced physical strength, reduced physical endurance, and/or impaired mood.08-04-2011
20110190229COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING - A method for preventing hyperpigmented skin, undesired pigmentation disorder of skin, or undesired darkening of skin using coumarin compounds, the use of such compounds, and compositions and formulations thereof are disclosed. In a particular embodiment, the coumarin compounds are selected from robustic acid methyl ether, scandenin, and coumophos. The compounds may be prepared as additives to pharmaceutical and cosmetic compositions, and in personal care products such as antiperspirants. In a particular embodiment extends to an antiperspirant product containing a skin darkening inhibitory amount of a compound of the invention. Also, the present skin darkening compounds may be prepared in combination with each other. The compounds, compositions and formulations of the invention may be used for the prevention of the onset or progression of conditions characterized by unwanted skin darkening, including those that may be causally related to aberrant melanogenesis activity including, by way of non-limiting example, hyperpigmentation and others.08-04-2011
20100029578Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds - The invention disclosed herein relates generally to compounds and methods useful in treating or preventing atrial fibrillation (AF).02-04-2010
20100022464FUNCTIONAL FOOD COMPOSITION THAT IS RICH IN PHENOLIC COMPOUNDS AND USE OF SAID COMPOSITION - The invention relates to a functional food composition rich in phenolic compounds, obtained from the combination of citric and olive species extracts, comprising: between 5 and 25% of oleuropein; between 0.1 and 1% of verbascoside, between 0.1 and 1% of hydroxytyrosol, between 1 and 5% of neohesperidin; between 1 and 10% by weight of naringin; between 0.5 and 5% of naringenin and between 0.1 and 2% of apigenin, and its use in food products and supplements.01-28-2010
20110218163Paeoniflorin Preparations and Uses Thereof for Fat Reduction - Disclosed are methods and preparations useful for reducing fat at a targeted area(s) on a human. The preparations comprise as an active ingredient an adipolysis enhancing (i.e., fat-melting) amount of an active ingredient, paeoniflorin (PF). The preparations may be provided as an injectable preparation or as a topically applied preparation, such as in the form of a crème or lotion. In topical preparations, the active ingredient paeoniflorin may be contained within nanospheres, such as albumin nanospheres. The PF-containing preparations may also include a permeant, such as azone. The method may be accompanied by the application of ultrasound to the area being treated prior to, during or after, or prior to, during, and after application of the paeoniflorin preparation to an area of the body in which fat reduction is desired. By way of example, the methods and preparations are effective for reducing targeted fat deposits at various anatomical sites of the body, such as the midsection (“love handles”), jowls, hips, arms, thighs and buttocks area.09-08-2011
200900543561-SUBSTITUTED-7-(B-D-GLYCOPYRANOSYLOXY)(AZA)INDOLE COMPOUND AND PHARMACEUTICAL CONTAINING THE SAME - [Objective] The present invention provides a compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity or the like. 02-26-2009
20100234310ESTROGENIC COMPOUNDS AND THEIR METHODS OF USE - Isolated compounds and combinations of isolated compounds isolated from 09-16-2010
20120040921COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising 5-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.02-16-2012
20100227828NEW SYNERGISTIC PHYTOCHEMICAL COMPOSITION FOR THE TREATMENT OF OBESITY - Synergistic anti-adipogenic and pro-lipolytic compositions for the prevention and amelioration of adipogenesis and lipolysis mediated diseases, comprising at least two extracts selected from enriched demethylated curcuminoids obtained from 09-09-2010
20090105164SUBSTITUTED INDOLE-O-GLUCOSIDES - Substituted indole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.04-23-2009
20090036386Heterobifunctional compounds for selectin inhibition - Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise glycomimetics linked to a compound, for example a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).02-05-2009
20090325891Cartilage regeneration-promoting agent - An object of the present invention is to provide an excellent cartilage regeneration-promoting agent that can promote regeneration of cartilage efficiently and is highly safe, and a medicine and a food that utilizes the cartilage regeneration-promoting agent. Thus, the present invention relates to a cartilage regeneration-promoting agent that includes at least one of hydroxytyrosol and a precursor of hydroxytyrosol, and to a medicine and a food that includes the cartilage regeneration-promoting agent.12-31-2009
20120252745NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES - The disclosure provides novobiocin analogues with noviose replacements which are useful as Hsp90 inhibitors in the treatment of cancer.10-04-2012
20100216728NEW USE OF SPECIFIC CYKLOLIGNANS - The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9′ have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin.08-26-2010
20120004189COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.01-05-2012
20110059912COMBINATION THERAPY COMPRISING SGLT INHIBITORS AND DPP4 INHIBITORS - The present invention relates to combination therapy comprising a DPP4 inhibitor and an SGLT inhibitor. The combination of the present invention leads to increase plasma GLP-1 level and the combination is useful for prevention or treatment of conditions such as diabetes and diseases related to diabetes.03-10-2011
20110166088BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS - The present invention provides Gyrase B and/or Topoisomerase IV par E inhibitors, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed by gram positive, gram negative and anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, 07-07-2011
20110166089SOLUTION FOR TISSUE ADHESION PREVENTION AND METHOD FOR TISSUE ADHESION PREVENTION - The objective of the invention is to provide a solution for tissue adhesion prevention and a method for tissue adhesion prevention that are applicable to general surgery and in which covering condition during surgery is stable and convenient. The invention is the solution for tissue adhesion prevention of which the active ingredient is trehalose. Also, it contains at least one or more among antioxidants, chelates, antiseptics, hemostatics, anti-inflammatory agents, and polysaccharides, mucopolysaccharides, salts of polysaccharides and salts of mucopolysaccharides having lubricating properties. This solution for tissue adhesion prevention is provided as any form of perfusion fluid, spray fluid, solution for spray or vaporization administration, foam-like aerosol preparation, injection solution for intravenous fluids, intravenous fluid.07-07-2011
20120022010USE OF FLAVONOIDS TO INCREASE THE BIOAVAILABILITY OF HESPERETIN - The present invention relates generally to the field of hesperetin bioavailability. One embodiment of the present invention is directed at a composition that allows to increase the bioavailability of hesperetin and consequently to maximize the beneficial health effects of hesperetin.01-26-2012
20100184712HYPERBRANCHED POLYMERS BASED ON CYCLODEXTRINS AND POLY (AMIDOAMINES) FOR THE CONTROLLED RELEASE OF INSOLUBLE DRUGS - Hyperbranched, water-soluble polymers, obtainable by Michael polyaddition of α-, β-, or γ-cyclodextrins and amines to bisacrylamides.07-22-2010
20100227826Stable Flavonoid Solutions - A stable flavonoid solution comprising (i) at least one flavonoid or flavonoid derivative selected from the group consisting of luteolin, myricetin, baicalin, baicalein, silymarin and kushenol, (ii) a mixture of alkyl glycols of two to seven carbon atoms, (iii) a polyol ether and (iv) an antioxidant.09-09-2010
20120208777DIOSMETIN COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Compounds of formula (I):08-16-2012
20120065153AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF - The invention concerns heparanase inhibiting compounds of general formula (I) wherein R represents a hydrogen atom, an hydroxyl radical, a —OSO03-15-2012
20100222287Therapeutic Cancer Treatments - Provided are methods for treating prostate cancer by administering a therapeutically effective amount of a hedgehog inhibitor.09-02-2010
20120071428NANOCRYSTALLINE PHOTOCATALYTIC COLLOID, A METHOD OF PRODUCING IT AND ITS USE - The present invention relates to a nanocrystalline photocatalyst active upon visible light irradiation, with a high degree of dispersion, stable in the form of a transparent colloidal solution in an aqueous environment, containing nanocrystals of titanium dioxide (TiO03-22-2012
20130184228MUSCADINE COMPOSITIONS WITH ANTI-OXIDANT ACTIVITY - Antioxidant compositions are disclosed that include muscadine pomace extract and resveratrol from a source other than muscadine. In other examples the composition also includes polyphenols from a source other than muscadine. The compositions increase the expression of antioxidant genes and/or genes associated with mitochondrial biogenesis.07-18-2013
20120316123DIETARY SUPPLEMENT COMPOSITION OF CITRUS DERIVATIVES - There is disclosed a dietary supplement composition of alkaloids and flavonoids extracted from citrus fruits that exhibits lipolytic and thermogenic activity and increases RMR, while at the same time exhibiting no negative side effects such as increase in blood pressure or heart rate. The composition essentially comprises two components: (A) the protoalkaloids synephrine, tyramine, N-methyltyramine, hordenine and octopamine; and (B) at least one of hesperidin, naringin and mixtures thereof.12-13-2012
20090131340USE OF FLAVONOIDS AS IMMUNOMODULATING OR IMMUNO-PROTECTIVE AGENTS IN COSMETIC AND DERMATOLOGICAL PREPARATIONS - A method of treating or prophylactically treating immunosuppression or allergic and inflammatory symptoms of skin caused by UVB radiation which comprises applying to the skin a cosmetic or dermatological composition which comprises one or more flavonoids.05-21-2009
20110183930WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES - The invention relates to the preparation of phenolics derivatives by enzymatic condensation of phenolics selected among pyrocatechol or its derivatives with the glucose moiety of sucrose. The production of said phenolics derivatives is achieved with a glucosyltransferase (EC 2.4.1.5). These O-α-glucosides of selected phenolics are new, have a solubility in water higher than that of their parent polyphenol and have useful applications in cosmetic and pharmaceutical compositions, such as antioxidative, antiviral, antibacterial, immune-stimulating, antiallergic, antihypertensive, antiischemic, antiarrythmic, antithrombotic, hypocholesterolemic, antilipoperoxidant, hepatoprotective, anti-inflammatory, anticarcinogenic, antimutagenic, antineoplastic, anti-thrombotic and vasodilatory formulations, or in any other field of application.07-28-2011
20110183929STANDARDIZED EXTRACT AND FRACTION FROM HANCORNIA SPECIOSA LEAVES AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention describes a standardized extract obtained from the leaves of 07-28-2011
20120165278Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Compositions And Methods For Preparing And Using Same - The present invention relates to pyrroloquinolinyl-pyrrolidine-2,5-dione compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing pyrroloquinolinyl-pyrrolidine-2,5-dione compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds or pharmaceutical compositions to subjects in need thereof.06-28-2012
20120214755METHODS OF PRODUCING AND USING NUTRITIONAL AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ONE OR MORE ACTIVE SUBSTANCES - Methods for producing a composition that includes an active agent, nutraceutical and pharmaceuticals compositions, and methods for ameliorating and/or treating a disease using the composition that includes an active substance are described herein. More particularly, methods for producing a composition that contains one or more active substances such as oleocanthal, pharmaceutical compositions that include one or more active substances such as oleocanthal, and methods of ameliorating and/or treating inflammation using compositions that contains one or more active substances such as oleocanthal are described.08-23-2012
20100273727ORAL ADMINISTRATION COMPOSITION - A composition which has high safety and is excellent in the effect of reducing body fat, such as visceral fat, subcutaneous fat and the like, and neutral fat, and a food, a pharmaceutical and a feed comprising the same, are provided.10-28-2010
20100273726METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS ACTIVE METABOLITES ISOLATED FROM LAURUS NOBILIS AND COMBINATIONS THEREOF - This present provides kaempferol-3-(2-E,3-Z-di-p-coumaroyl)-rhamnoside, kaempferol-3-(2-Z-3-E-di-p-coumaroyl)-rhamnoside, and kaempferol-3-(2,3-di-Z-p-coumaroyl)-rhamnoside compounds useful as a new class of anti-bacterial agents. These compounds are extracted from 10-28-2010
20100016245RHAMNOSE SUBSTITUENTS OF SL0101 AND THERAPEUTIC USES THEREOF - The present invention provides compositions and methods useful for preparing and using analogs, derivatives, and modifications of kaempferols that have anti-neoplastic activity. More specifically, the compounds are analogs, derivatives, and modifications of SLO1O1. The invention further provides compounds that are inhibitors of rsk activity. The invention further provides compounds that selectively inhibit excessive rsk activity in cancers. The present invention further provides methods for treating cancer using compounds of the invention.01-21-2010
20100292178Method of treating non-insulin dependent diabetes mellitus and related complications - A method of restoring insulin beta cells in a living object to lower a plasma sugar level comprising the step of providing a composition of berberine and catalpol as the two major active ingredients of said composition. The composition is preferably include oleanolic acid and taurine as active ingredients. The composition is pre-made into a single dosage unit. The single dosage contains active ingredients within a range between 1 to 300 mg/kg/dl for a single intake and is in a form of packet powders, solution in vials, ampoules or pre-filled syringes, capsule, tablet, draught in water, syrup and/or cachets. The berberine is obtained from natural herbs 11-18-2010
20100292177Methods of treatment using combination therapy - Provided herein are methods of treating a proliferative disease in a subject, comprising administering to the subject a therapeutically effective amount of AC220 and a nucleoside analog, a topoisomerase inhibitor or an anthracycline, or a combination thereof.11-18-2010
20120220545COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF - Provided are coumarin compounds of formula I, for example, robustic acid methyl ether, and the use of such compounds and compositions thereof to modulate (e.g., inhibit) melanogenesis and pigmentation.08-30-2012
20120083461AGENT FOR INHIBITING PERITONEAL MEMBRANE THICKENING04-05-2012
20120083460READILY WATER-SOLUBLE ISOQUERCITRIN COMPOSITION - Disclosed is a method for improving the solubility of isoquercitrin in water. Also disclosed is a readily water-soluble isoquercitrin composition which has improved solubility in water due to the method. Specifically disclosed is a method for preparing an isoquercitrin inclusion product, which comprises including isoquercitrin in γ-cyclodextrin in the proportion of 2 to 10 mol of γ-cyclodextrin to 1 mol of isoquercitrin.04-05-2012
20090170787COSMETIC COMPOSITION CONTAINING HYDROLYSATES OF ICARIIN - The present invention relates to a cosmetic composition containing hydrolysates of icariin, and more particularly, a cosmetic composition containing hydrolysates of icariin including icaritin, icariside I and icariside II. The hydrolysates of icariin is prepared by a method comprising the steps of: (a) obtaining an extract from a plant containing icariin using water or an organic solvent; and (b) hydrolyzing the plant extract with an acid, a base, an enzyme or a microorganism producing the enzyme. The cosmetic composition according to the present invention is employed for anti-oxidant, anti-aging, whitening or anti-wrinkling effects.07-02-2009
20100240603EXPRESSION INHIBITOR OF NUCLEAR TRANSCRIPTION FACTOR AP-1 AND PHARMACEUTICALS AND PRODUCTS USING THE SAME - An expression inhibitor of a nuclear transcription factor AP-1 is provided that is excellent in safety and activity of inhibiting the expression of a nuclear transcription factor AP-1. The AP-1 expression inhibitor of the present invention is characterized by containing chamaemeloside. In the present invention, chamaemeloside may be contained as an extract of Roman chamomile or German chamomile. The chamaemeloside is contained in Roman chamomile or German chamomile. Conventionally, Roman chamomile and German chamomile have been used as cosmetic materials and herb teas and have no problems in safety. An extract of Roman chamomile or German chamomile and chamaemeloside inhibit the expression of the AP-1 at the gene level (see FIG. 09-23-2010
20080300198Olive Compositions and Methods for Treating Inflammatory Conditions - A method of treating an inflammatory condition with a hydroxytyrosol-rich composition. Improvement is monitored as a reduction in the levels of a biochemical marker such as homocysteine or C-reactive protein. The composition may be administered in an amount and for a period sufficient to effect a drop in the level of the biochemical marker.12-04-2008
20110003762METHODS AND COMPOSITIONS FOR THE TREATMENT OF OBESITY, INSULIN RELATED DISEASES AND HYPERCHOLESTEROLEMIA - A process of enhancing insulin excretion in a subject includes administering to the subject a polyphenol active ingredient. The polyphenol active ingredient is a purified cyanidin-3-glycoside alone or purified cyanidin alone. The pharmaceutically acceptable carrier is administered with the polyphenol active ingredient.01-06-2011
20110028416NUTRITIONAL COMPOSITIONS FOR PROMOTION OF BONE GROWTH AND MAINTENANCE OF BONE HEALTH COMPRISING EXTRACTS OF FOR EXAMPLE ROSEMARY OR CARAWAY - Compositions and methods for maintenance of bone health or prevention, alleviation and/or treatment of bone disorders are presented. The present invention also provides the manufacture of a nutritional product, a supplement or a medicament for promoting bone growth or for the maintenance of bone health and methods regarding same. In an embodiment, the present invention provides a composition comprising an active ingredient having an effective amount of a plant or plant extract containing at least one phytochemical having the ability to induce bone morphogenic protein expression.02-03-2011
20120322754NOVEL USE FOR SCOPOLIN AND DERIVATIVES THEREOF - The present invention relates to a novel use for the compound of Chemical formula 1 in order to produce drugs or foods for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like, and to a composition for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like which contains the compound of Chemical formula 1 as an active ingredient, and also to a method for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like comprising the administration of the compound of Chemical formula 1 to a mammal in a therapeutically effective dose. According to the present invention, the compound of Chemical formula 1 has been confirmed to suppress the differentiation of adipocytes, to reduce body weight and the amount of visceral fat, to reduce concentrations of cholesterol, triglycerides, free fatty acids and glucose which are associated with fatty liver and diabetes and the like and to reduce the fatty component in liver tissue, to suppress gene expression associated with obesity in visceral fatty tissue, and to increase the amount of expression of UCP1 and UCP3 which are UCP (uncoupling protein) genes involved in thermogenesis. The compound of Chemical formula 1 can be used to advantage in order to prevent or treat obesity, fatty liver, diabetes, metabolic syndrome and the like since, unlike the obesity treating agents based on synthetic drugs currently in use, it is based on a natural substance and hence entails a very low risk of adverse effects and, additionally, it exhibits its pharmacological effects by regulating the expression of genes associated with obesity rather than exhibiting pharmacological effects by acting on enzymes or the nervous system.12-20-2012
20110046081CLASSICAL CANNABINOID METABOLITES AND METHODS OF USE THEREOF - The present invention encompasses classical cannabinoid metabolites and uses thereof.02-24-2011
20120270820USE OF ALBIFLORIN FOR ANTI-DEPRESSION - A pharmaceutical composition containing albiflorin and use thereof in manufacturing medicaments for preventing and treating depression are provided by the present invention.10-25-2012
20120270821CDK5 Inhibitors and Therapeutic Uses Thereof - Natural occurring inhibitors of cyclin-dependent protein kinase 5 (Cdk5), isolated from the root of 10-25-2012
20110218164THERAPEUTIC, DIETARY OR COSMETIC USE OF COMPOUNDS WITH SPECIFIC ANTI-APOPTOTIC ACTIVITY TOWARD CASPASE-3, AND COMPOSITIONS CONTAINING THESE COMPOUNDS - This invention regards the use of zeaxanthin and/or rutin, as such or further combined with spermidine, as the active principle in a pharmaceutical, dietary, or cosmetic composition, acting to inhibit caspase-3 and therefore to control apoptosis by preventing programmed cell death.09-08-2011
20110237533NOVEL POLYPHENOL COMPOUND - Compounds represented by formula (I)09-29-2011
201102375321-[(3-CYANO-PYRIDIN-2-YL)METHYL]-3-METHYL-7-(2-BUTYN-1-YL)-8-[3-(R)-AMINO-- PIPERIDIN-1-YL]-XANTHINE FOR THE TREATMENT OF A METABOLIC DISORDER OF A PREDOMINANTLY CARNIVOROUS NON-HUMAN ANIMAL - The present invention provides a pharmaceutical composition comprising 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine or a pharmaceutically acceptable form thereof as pharmaceutically active compound for the therapy of a metabolic disorder or metabolic disease of a predominantly carnivorous non-human animal. It is especially useful for the therapy of diabetes and related diseases of predominantly carnivorous mammals like cats or dogs. The invention further provides respective uses of such compositions and of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine or pharmaceutically acceptable forms thereof.09-29-2011
20120277173STABILIZED ANTHOCYANIN COMPOSITIONS - The invention describes stabile anthocyanin compositions, methods to prepare such compositions and also methods of use of such compositions to treat various afflictions. The present invention describes unique compositions of an anthocyanin and a stabilizing compound such that the combination of the two components provides that the anthocyanin does not readily undergo degradation, such as oxidation, pH instability, etc.11-01-2012
20120329739COMPOSITION FOR PREVENTING OR TREATING POLIOSIS OR VITILIGO COMPRISING A PUERARIA GENUS PLANT EXTRACT OR PUERARIN - Disclosed is a composition for preventing or treating poliosis or vitiligo comprising a 12-27-2012
20100261664Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof - Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof10-14-2010
20130012463IDENTIFICATION OF FREE-B-RING FLAVONOIDS AS POTENT COX-2 INHIBITORS - The present invention provides a novel method for inhibiting the cyclooxygenase enzyme COX-2. The method is comprised of administering a composition containing a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids to a host in need thereof. The present also includes novel methods for the prevention and treatment of COX-2 mediated diseases and conditions. The method for preventing and treating COX-2 mediated diseases and conditions is comprised of administering to a host in need thereof an effective amount of a composition containing a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids and a pharmaceutically acceptable carrier.01-10-2013
20130018007Modified Saponins for the Treatment of Fungal Infections - Methods of treating a fungal infection in a subject, the method comprising administering to the subject a modified saponin.01-17-2013
20080255059Regulators of the hedgehog pathway, compositions and uses related thereto - The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations.10-16-2008
20080242622Identification of genetic alterations that modulate drug sensitivity in cancer treatments - This invention features methods of identifying genetic alterations that can modulate cancer cells' sensitivity to an anti-cancer drug. Information on such genetic alterations can be used to predict cancer therapeutic outcomes and to stratify patient populations to maximize therapeutic efficacy.10-02-2008
20080227729PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTIOUS AND OTHER DISEASES WITH IMMUNOEFFECTOR COMPOUNDS - Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ cyclic AGPs for selectively stimulating immune responses in animals and plants.09-18-2008
20080227728Therapeutic Agent for the Treatment of a Condition Associated with Peripheral Vascular Disease - The present invention comprises the use of oleuropein in the preventive and/or therapeutic treatment of a condition associated to the peripheral vascular disease, particularly to venous insufficiency.09-18-2008
20080227727Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors - Disclosed are methods and compositions useful in identifying an E3 ubiquitin ligase inhibitor and modulating cell growth, comprising contacting a cell with an effective amount of an inhibitor of an E3 ubiquitin ligase, and contacting the cell with an effective amount of a topoisomerase inhibitor, wherein the treatment with the E3 ubiquitin ligase inhibitor and topoisomerase inhibitor modulates cell growth in comparison to a cell treated with the topoisomerase inhibitor alone. The present invention further provides methods for identifying and making an E3 ubiquitin ligase inhibitor.09-18-2008
20080221045Hepatic Function-Improving Agent - An object of the present invention is to provide a means for improving hepatic function of mammals including humans to normal condition. The present invention achieves the above object by providing a hepatic function-improving agent comprising α-glucosyl-hesperidin as an effective ingredient.09-11-2008
20130137649EPIGENETIC MECHANISMS OF ANTI-FIBROTIC ACTION FOR THE LIVER - This invention demonstrates the therapeutic efficacy of Yang-Gan-Wan (YGW) and its active components, especially in the formulation provided by Sheng-Pu Pharmaceutials, Inc., for treating and preventing liver fibrosis. This invention further demonstrates MeCP2 is an important therapeutic target for YGW and its active ingredients' action against liver fibrosis and cirrhosis.05-30-2013
20130116204(METHYLSULFONYL) ETHYL BENZENE ISOINDOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USES - Provided are (methylsulfonyl)ethyl benzene isoindoline compounds, and pharmaceutically acceptable salts, solvates, or stereoisomers thereof. Methods of use and pharmaceutical compositions of these compounds are also disclosed.05-09-2013
20130096076PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR - The invention relates to a pharmaceutical composition according to claim 04-18-2013
20130096075COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF METABOLIC SYNDROME - A composition comprising (a) and (b), and a food or drink or a medicine comprising the composition, wherein 04-18-2013
20130131000Composition Comprising Ligustroflavone, Rhoifolin and Hyperin and Its Pharmaceutical Application - Disclosed is a composition comprising ligustroflavone, rhoifolin and hyperin, which is prepared according to rational weight ratio: 40% to 80% ligustroflavone, 5% to 45% rhoifolin and 1% to 40% hyperin. The composition can be used as a neuraminidase inhibitor for preventing and treating influenza, and can be formulated into pharmaceutically acceptable dosage forms.05-23-2013
20130130999METHOD OF DETERMINING ACUTE MYELOID LEUKEMIA RESPONSE TO TREATMENT WITH FARNESYLTRANSFERASE INHIBITORS - The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients.05-23-2013
20100279962MONOSEBACATE OF PYRAZOLE DERIVATIVE - The present invention provides a novel form of 3-(3-{4-[3-(β-D-glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl]-3-methylphenoxy}propylamino)-2,2-dimethylpropionamide with improved storage stability. Since bis[3-(3-{4-[3-(β-D-glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl]-3-methylphenoxy}propylamino)-2,2-dimethylpropionamide] monosebacate has extremely excellent storage stability, it is useful as a drug substance. Furthermore, it shows an extremely good crystalline property and can be purified by a convenient method, and therefore is suitable for the industrial preparation.11-04-2010
20080200402Use Of Fumagillin And The Derivatives Thereof To Increase The Bioavilability Of The Macrocyclic Lactones - The invention relates to the use of fumagillin and the analog derivatives thereof, as inhibitors of cellular transporters, such as ABC transporters, and especially of P-glycoprotein, in order to increase the bioavailability of active ingredients that can be used in the treatment of pathologies such as cancers or parasitic diseases, and especially in order to increase the bioavailability of the macrocyclic lactones.08-21-2008
20110251145Phytoestrogenic Compositions for Preventing or Treating Symptoms Associated with Menopause - The present invention relates to a pharmaceutical composition for preventing or treating a menopausal symptom, comprising cinnamic acid, shanzhiside methylester or a mixture thereof as an active ingredient. The composition of the present invention exhibits an excellent estrogenic activity, and is effectively utilized for treating or preventing diverse menopausal symptoms generated by estrogen deficiency during perimenopause, menopause and postmenopause.10-13-2011
20090192098METHOD FOR TREATING HEMATOPOIETIC NEOPLASMS - This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent.07-30-2009
20110275581NUCLEAR EXPORT INHIBITORS OF TOPOISOMERASE II ALPHA - A method of treating cancer in a subject comprising the step of administering to the subject in need thereof an effective amount of a combination of a compound that binds a nuclear export signal (NES inhibitor) on topoisomerase IIα and a topoisomerase inhibitor. Twenty small molecule inhibitors (SMI) that bind to the two nuclear export sequences (NES) topo IIα have been identified from the NCI database using computer-generated molecular modeling. These SMI will improve the effectiveness of topo II directed therapeutics, particularly in the treatment of diseases such as multiple myeloma (MM). In vitro apoptosis assays indicate that these drugs may be effective as single agents or in combination with currently used cancer drugs that target topo II.11-10-2011
20110275580BICYCLIC DERIVATIVES OF MORPHINE-6-GLUCURONIDE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS - The disclosure relates to compounds of formula (I):11-10-2011
20110275579ANTI-DIABETIC EXTRACT OF ROOIBOS - Novel and useful compositions derived from rooibos for treating diabetes are provided. The present invention is particularly concerned with the treatment of Type 2 diabetes. The invention provides a new use for aspalathin and rutin and compositions containing them for use in the prevention and treatment of diabetes. The invention provides an antidiabetic agent, an anti-diabetic composition containing the anti-diabetic agent, a foodstuff or beverage containing the anti-diabetic agent, a method for preventing or treating diabetes or impaired glucose tolerance, and a method of decreasing blood glucose level. The anti-diabetic agent may be an extract from rooibos (11-10-2011
20130150314TRIOXACARCINS AND USES THEREOF - The present invention relates to trioxacarcin compounds of the formula: (I) or pharmaceutically acceptable forms thereof; wherein R06-13-2013
20100311676COMPOSITIONS CONTAINING SESAMIN-CLASS COMPOUND(S) AND QUERCETIN GLYCOSIDE(S) - The purpose of the present invention is to provide a means of enhancing the bodily absorption of sesamin-class compounds. By using sesamin-class compounds and quercetin glycosides in combination, the bodily absorption of the sesamin-class compounds can be enhanced.12-09-2010
20100317605THE USE OF EPIMEDIUM FLAVONES AND EFFECTIVE COMPONENTS THEREOF FOR THE PREPARATION OF MEDICAMENTS OF PROMOTING PROLIFERATIONS AND DIFFERENTIATIONS OF NERVE CELLS - The use of epimedium flavones and/or icariins for the preparation of medicaments of promoting proliferations and/or differentiations of nerve cells, is disclosed.12-16-2010
20130184227Cytochrome P450 2C9 Inhibitors - This invention is to provide multiple specific inhibitors of cytochrome P450 isozyme CYP2C9. These inhibitors can be derived from any combinations with the following compounds including: Tamarixetin, Formononetin, isoliquritigenin, Phloretin, luteolin, Quercitrin, quercetin, myricetin, Wongonin, Puerarin, Genistein, Nordihydroguaiaretic acid, Narigenin, Capillarisin, Chrysin, Fisefin, eriodictyol, 6-Gingerol, Isorhamneti, isoquercitrin, Morin, (+)-Taxifolin, isovitexin, 3-Phenylpropyl Acetate, Oleanolic acid, ursolic acid, β-Myrcene, cinnamic acid, Luteolin-7-Glucoside, Liquiritin, (+) Limonene, Homoorientin, Swertiamarin, Embelin, Daidzein, Poncirin, (−)-Epicatechin, ergosterol. These natural products can be used to enhance the bioavailability of therapeutic agents (drugs).07-18-2013
20120283204TALARAZOLE METABOLITES - Novel metabolites of talarazole of formula (I) have been isolated and characterized, wherein R═H, OH, OSO11-08-2012
20120283203METHODS AND COMPOSITIONS FOR THE TREATMENT OF OBESITY, INSULIN RELATED DISEASES AND HYPERCHOLESTEROLEMIA - A process of enhancing insulin excretion in a subject includes administering to the subject a polyphenol active ingredient. The polyphenol active ingredient is a purified cyanidin-3-glycoside alone or purified cyanidin alone. The pharmaceutically acceptable carrier is administered with the polyphenol active ingredient.11-08-2012
20110312906TREATMENT OR REDUCTION OF MENOPAUSAL SYMPTOMS - There is described a method for the treatment or prevention of menopausal symptoms or osteoporosis wherein there is administered to a subject in need of such treatment a therapeutically effective amount of the isotlavone formononetin, or a method for the treatment or prevention of menopausal symptoms wherein there is administered to a subject in need of such treatment a therapeutically effective amount of the isoflavone daidzein, the isotlavone being optionally administered with one or more pharmaceutically acceptable adjuvants, carriers and/or excipients. Therapeutic uses and compositions/foods are also described, comprising daidzein or formononetin optionally in association with one or more pharmaceutically acceptable adjuvants, carriers, food components and/or excipients.12-22-2011
20110312905STIMULUS-TRIGGERED PRODRUGS - Set forth herein, inter alia, are compositions and methods for treating diseases with prodrugs. Provided herein are prodrug compositions for inhibiting the function of proteins, compositions and methods for treating diseases associated with oxidative compounds, oxidatively-sensitive prodrugs of inhibitors of metalloproteases. and methods of inhibiting metalloproteases using oxidatively-sensitive prodrugs.12-22-2011
20110312904COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES - The present invention provides compounds of Formula (I), compositions comprising an effective amount of a compound of Formula (I), optionally with chemotherapeutic drugs such as a tubulin-binding drug, and methods of their use for reducing the toxicity of cytotoxic agents, treating or preventing cancer or a neuropathic disorder, inducing a chemoprotective phase II enzyme, DNA, or protein synthesis, enhancing the immune system, treating inflammation, improving and enhancing general health or well-being, and methods for making compounds of Formula (I).12-22-2011
20130190258COMPOUNDS FOR INHIBITION OF CANCER CELL PROLIFERATION - Methods and small molecule compounds for inhibition of cancer cell proliferation are provided. One example of a class of compounds that may be used is represented by the compound of Formula I or a pharmaceutically acceptable salt, N-oxide or solvate thereof, wherein A, B, D, E, F, G, I, J, R, R07-25-2013
20100069313NOVEL POWDERS BASED ON VEGETATION WATER FROM OLIVE OIL PRODUCTION - The present invention is directed a process for the manufacture of a powder comprising vegetation water rich in water-soluble polyphenols, especially rich in hydroxytyrosol, as well as to the powders themselves and dietary supplements, especially in form of tablets, food, feed and cosmetic preparations containing such powders. The process comprises the following steps: A) providing vegetation water (concentrate) containing water-soluble polyphenols; B) (optionally) modifying the water content of the vegetation water (concentrate); C) optionally centrifuging the vegetation water (concentrate) and separating the water-soluble part; D) spray-drying or granulating the (water-soluble part of the) vegetation water (concentrate), preferably in presence of an adjuvant; E) optionally washing the thus obtained powder comprising vegetation water rich in water-soluble polyphenols with an organic solvent.03-18-2010
20130196937AGE PRODUCTION INHIBITOR - Disclosed is an AGE production inhibitor or the like, which effectively inhibits the production of an advanced glycation end product (AGE), while having improved biological safety. Specifically disclosed is an AGE production inhibitor or the like, which contains en extract of cherry tree (preferably blossoms or leaves thereof) and/or a processed product of the extract as an active substance. The AGE production inhibitor or the like contains, as an active substance, at least one compound that is selected from among 1-O-(E)-Caffeoyl-β-D-glucopyranoside, 1-O-(E)-Coumaroyl-β-D-glucopyranoside, 1-O-(E)-Cinnamoyl-β-D-glucopyranoside, Kaempferol 3-O-β-D-glucopyranoside, Quercetin 3-O-β-D-glucopyranoside, Kaempferol 3-O-(6″-malony)-β-D-glucopyranoside, and Quercetin 3-O-(6″-malony)-β-D-glucopyranoside.08-01-2013
20130196938COMBINATION COMPRISING CNDAC (2'-CYANO-2'-DEOXY-N4-PALMITOYL-1-BETA-D-ARABINOFURANOSYL-CYTOSINE) AND A CYTOTOXIC AGENT - A first aspect of the invention relates to a combination comprising 2′-cyano-2′-deoxy-N08-01-2013
20120094945Discovery of Selective Glucocorticoid Receptor Modulators by Multiplexed Reporter Screening - The invention relates to assays to detect selective gene regulation by ligand dependent transcription factors. The invention also relates to selective modulators of the glucocortocoid receptor for treatment of inflammation and allergic and immune-mediated diseases.04-19-2012
20130210753METHODS OF TREATING MUSCULAR DYSTROPHIES - The invention relates to methods of treating Duchenne muscular dystrophy with flavonoids. The methods may include (a) providing a pharmaceutical composition comprising a therapeutically effective amount of flavonoid, and (b) administering the composition to a human patient, wherein the flavonoid comprises an isoflav-4-one with at least one of the carbons located at positions 8, 7, 6, 5, 2, 2′, 3′, 4′, 5′, or 6′ modified by an alcohol group. Alternatively, the flavonoid may comprise (1) a flavan-3-ol with at least one of the carbons located at positions 8, 7, 6, 5, 4, 2′, 3′, 4′, 5′, or 6′ modified by an alcohol group, or (2) a Free-B-Ring flavone with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by an alcohol group and with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by a glycoside group.08-15-2013
20130210754METHOD FOR PRODUCING AN ENRICHED EXTRACT FROM VITIS VINIFERA L. LEAVES - The present application relates to a process for preparing an extract of leaves of 08-15-2013

Patent applications in class Oxygen of the saccharide radical bonded directly to a nonsaccharide hetero ring or a polycyclo ring system which contains a nonsaccharide hetero ring

Patent applications in all subclasses Oxygen of the saccharide radical bonded directly to a nonsaccharide hetero ring or a polycyclo ring system which contains a nonsaccharide hetero ring